AR023308A1 - Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen. - Google Patents

Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.

Info

Publication number
AR023308A1
AR023308A1 ARP990101778A ARP990101778A AR023308A1 AR 023308 A1 AR023308 A1 AR 023308A1 AR P990101778 A ARP990101778 A AR P990101778A AR P990101778 A ARP990101778 A AR P990101778A AR 023308 A1 AR023308 A1 AR 023308A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
hydroxyl
phenyl
halogen
Prior art date
Application number
ARP990101778A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR023308A1 publication Critical patent/AR023308A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Uso de dihidropirimidinas de formula general 1 o bien de su forma mesomera (1a) en las cuales R1 representa fenilo, furilo, tienilo, triazolilo, piridilo,cicloalquilo C3-6 o representa restos de formulas 2, 3 o 4 estando los sistemas anulares indicados anteriormente eventualmente mono- o multisustituídos porsustituyentes iguales o distintos elegidos del grupo: halogeno, trifluorometilo, nitro, ciano, trifluorometoxi, carboxilo, hidroxilo, alcoxi (C1-6),alcoxicarbonilo (C1-6) y alquilo (C1-6) que, por su parte, puede estar sustituído por arilo con C6-10 o halogeno, y/o los sistemas anulares indicados estáneventualmente sustituídos por grupos de formula -S-R6, NR7R8, CO-NR9R10, SO2-CF3 y -A-CH2-R11, donde R6 significa fenilo que está eventualmente sustituído porhalogeno, R7, R8, R9 y R10 son iguales o distintos y significan hidrogeno, fenilo, fenilo sustituído por hidroxilo, hidroxilo, acilo (C1-6) o alquilo (C1-6)que, por su parte, puede estar sustituído por hidroxilo, alcoxicarbonilo (C1-6), fenilo o fenilo sustituído por hidroxilo, A significa un resto O, S, SO o SO2,R11 significa fenilo que está eventualmente mono- a multisustituído por sustituyentes iguales o distintos elegidos del grupo: halogeno, nitro, trifluorometilo,alquilo (C1-6) y alcoxi (C1-6), R2 representa un resto de formula -XR12 o -NR13R14, donde X significa un enlace u oxígeno, R12 significa hidrogeno,alcoxicarbonilo (C1-6) lineal o ramificado o un resto hidrocarburo (C1-8) lineal, ramificado o cíclico, saturado o insaturado que eventualmente contiene uno odos eslabones heteroátomos iguales o distintos del grupo O, CO, NH, -NH-alquilo (C1-4), -N-(alquilo (C1-4))2, S o SO2 y que está eventualmente sustituído porhalogeno, nitro, ciano, hidroxilo, arilo conC6-10 o arilalquilo con C6-10, heteroarilo o un grupo de formula -NR15R16, donde R15 y R16 son iguales o distintosy significan hidrogeno, bencilo o alquilo (C1-6), R13 y R14 son iguales o distintos y significan hidrogeno, alquilo (C1-6) o cicloalquilo con C3 a 6, R3representa hidrogeno, amino o representa un resto de formula 5, o representa formilo, ciano, alquiltío (C1-6) sustituído por hidroxilo, trifluorometilo o
ARP990101778A 1998-04-18 1999-04-16 Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen. AR023308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19817265A DE19817265A1 (de) 1998-04-18 1998-04-18 Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe

Publications (1)

Publication Number Publication Date
AR023308A1 true AR023308A1 (es) 2002-09-04

Family

ID=7864973

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101778A AR023308A1 (es) 1998-04-18 1999-04-16 Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.

Country Status (12)

Country Link
US (1) US6436943B1 (es)
EP (1) EP1073642B1 (es)
JP (1) JP2002512233A (es)
AR (1) AR023308A1 (es)
AU (1) AU3813499A (es)
CA (1) CA2328733A1 (es)
DE (2) DE19817265A1 (es)
ES (1) ES2186354T3 (es)
GT (1) GT199900054A (es)
PE (1) PE20000426A1 (es)
SV (1) SV1999000048A (es)
WO (1) WO1999054312A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4289100A (en) * 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
WO2000078730A1 (fr) * 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Nouveaux derives dihydropyrimidiniques
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
DE10012549A1 (de) * 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
GB0201179D0 (en) * 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
KR100502394B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 2-[2-(4-모르포리노)에틸아미노]피리딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
KR100502395B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 4-[4-(4-모르포리노)아닐리노]피리미딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물.
GB0313250D0 (en) * 2003-06-09 2003-07-16 Angeletti P Ist Richerche Bio Therapeutic agents
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
AR067630A1 (es) 2007-07-12 2009-10-21 Novartis Ag Soluciones farmaceuticas de telbivudina y metodo de tratamiento
WO2013019967A1 (en) * 2011-08-02 2013-02-07 Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California Modulators of virus assembly as antiviral agents
EP2812324B1 (en) 2012-02-08 2021-09-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SG11201408791TA (en) 2012-08-24 2015-01-29 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
PE20150776A1 (es) 2012-09-10 2015-05-21 Hoffmann La Roche 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b
SG11201503475WA (en) * 2012-11-09 2015-05-28 Univ Indiana Res & Tech Corp Alternative uses for hbv assembly effectors
CN105188703A (zh) * 2013-03-20 2015-12-23 美国印第安纳大学研究和技术公司 荧光-hap：用于细胞中的hbv核的诊断性染色剂
AU2014352404B2 (en) 2013-11-19 2018-07-19 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
CN104672223B (zh) 2013-11-27 2018-03-13 广东东阳光药业有限公司 二氢嘧啶衍生物的制备方法及其中间体
RU2682672C2 (ru) 2014-03-28 2019-03-20 Саншайн Лейк Фарма Ко., Лтд. Соединения дигидропиримидина и их применение в фармацевтических препаратах
CN105859709B (zh) 2015-02-07 2018-12-04 广东东阳光药业有限公司 二氢嘧啶衍生物的复合物及其在药物中的应用
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
CN110475775B (zh) * 2017-03-31 2023-05-09 富士胶片株式会社 4-吡啶酮化合物或其盐、包含4-吡啶酮化合物的药物组合物及剂
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN108947996B (zh) * 2018-07-12 2022-01-18 山东大学 二氢嘧啶-磺酰胺类衍生物及其制备方法与应用
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
CN112778299B (zh) * 2019-11-04 2023-07-14 江苏恒瑞医药股份有限公司 哌嗪脲基类衍生物、其制备方法及其在医药上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (es) 1973-01-23 1975-11-14 Ciba Geigy Ag
DE3234684A1 (de) 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
JPH07110132B2 (ja) 1991-08-22 1995-11-22 日本モトローラ株式会社 電圧変換装置
JP3349781B2 (ja) 1993-08-30 2002-11-25 富士通株式会社 スイッチングレギュレータ電源装置
US5774319A (en) 1993-10-27 1998-06-30 Square D Company Energy validation arrangement for a self-powered circuit interrupter
US5638264A (en) 1993-12-27 1997-06-10 Hitachi, Ltd. Parallelized power supply system providing uninterrupted operation
JP3493840B2 (ja) 1995-10-27 2004-02-03 松下電工株式会社 電源装置
SE9702564D0 (sv) * 1997-07-02 1997-07-02 Astra Ab New compounds
US5929615A (en) 1998-09-22 1999-07-27 Impala Linear Corporation Step-up/step-down voltage regulator using an MOS synchronous rectifier

Also Published As

Publication number Publication date
JP2002512233A (ja) 2002-04-23
PE20000426A1 (es) 2000-06-25
US6436943B1 (en) 2002-08-20
GT199900054A (es) 2000-10-07
EP1073642A1 (de) 2001-02-07
DE59903174D1 (de) 2002-11-28
CA2328733A1 (en) 1999-10-28
AU3813499A (en) 1999-11-08
ES2186354T3 (es) 2003-05-01
SV1999000048A (es) 2000-07-04
EP1073642B1 (de) 2002-10-23
WO1999054312A1 (de) 1999-10-28
DE19817265A1 (de) 1999-10-21

Similar Documents

Publication Publication Date Title
AR023308A1 (es) Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.
AR015765A1 (es) Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento.
AR018187A1 (es) Derivados de 1,4-dihidro-1,3-diazinas y 3,4-dihidro-1,3-diazinas, procedimiento para su preparacion, medicamentos, procedimiento para la produccion de los mismos y el uso de los mismos para la produccion de medicamentos
AR018175A1 (es) Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados.
NO930201L (no) Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk
GT200100174A (es) Proceso para la fabricacion de acidos n-aril-antranilicos y sus derivados.
FI944217A0 (fi) Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AR013542A1 (es) Compuesto 5-azaquinoxalinico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farma
AR046781A1 (es) Derivados de imidazoquinolinas. composiciones farmaceuticas.
AR033306A1 (es) Compuestos
HUP0303652A2 (hu) Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
AR016010A1 (es) UN COMPUESTO DERIVADO DE ACIDO SULFONHIDROXAMICO AROMATICO INHIBIDOR DE METALOPROTEASAS, COMPUESTO INTERMEDIARIO, PROCESO PARA FORMARLO, COMPOSICION FARMACEUTICA Y USO PARA EL TRATAMIENTO DE UN ANIMAL HUESPED MAMíFERO.
CY1107703T1 (el) Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης
AR002710A1 (es) Derivados de n-(3-benzofuranil)urea, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, un procedimiento para preparardicha composicion farmaceutica y el uso de dichos derivados para la preparacion de medicamentos.
MX3277E (es) Procedimiento para la preparacion de derivados de eritromicina
FI862757A (fi) Pyridonkarbonsyraderivat och foerfarande foer framstaellning av dessa.
AR005233A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina, procesos para su preparacion, una composicion farmaceutica y el uso en la elaboracion de un medicamento
NO971625L (no) Nye peptider med immunomodulatoriske effekter
TR200401716T4 (tr) Yeni üç yerdeğiştirme gruplu fenil türevleri ve analogları
ES2062096T3 (es) Procedimiento para la obtencion de derivados del benzotriazol.
DE3782347D1 (de) Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel.
AR043186A1 (es) Indozolamidas dotadas de actividad analgesica, metodo de preparacion de las mismas y compuesto farmaceutico que las comprende
DE69710909D1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel